Advancing our understanding of FoxP3+CD25+CD4+ Tregs and utilizing FoxP3+CD25+CD4+ Tregs to selectively suppress the deleterious effects of excessive brain immunoreaction after stroke may provide novel therapeutic approaches for stroke patients. This evidence concerns the gene FOXP3 and stroke disorder.